ClearPoint Neuro, Inc. (CLPT) AI Stock Analysis

ClearPoint Neuro, Inc. is a medical device company headquartered in Solana Beach, California. It develops and commercializes platforms enabling minimally invasive brain surgery guided by direct intra-procedural MRI. Its core product, the ClearPoint system, enables the precise placement of deep brain stimulation electrodes, biopsy needles, laser catheters, and pharmaceutical infusions. It also offers the ClearPoint Neuro Navigation System for use in MRI suites. ClearPoint Neuro collaborates with partners such as Boston Scientific Corporation, Koninklijke Philips N.V., Blackrock Neurotech, The Johns Hopkins University, and the University of California, San Francisco.

ClearPoint Neuro's revenue increased from $16.3M in FY2021 to $37.0M in FY2025, generating a 5-year revenue CAGR of 23.6%. Gross margin sat at 61.4% in FY2025, down from 68.2% in FY2021. The business has sustained continuous operating losses, with an operating margin of -65.4% in FY2025 and -94.2% over the trailing twelve months. Annual net income was -$14.4M in FY2021, -$16.4M in FY2022, -$22.1M in FY2023, -$18.9M in FY2024, and -$25.5M in FY2025. Over the trailing twelve months, revenue totaled $42.3M, and quarterly revenue for the period ending June 30, 2026, increased 18.1% year-over-year.

As of June 30, 2026, ClearPoint Neuro held $29.4M in cash and short-term investments alongside total debt of $63.9M, resulting in net debt of $34.6M. Total assets stood at $86.7M against shareholders' equity of $10.8M, yielding a debt-to-equity ratio of 5.93 and a current ratio of 4.73. Cash flow remains negative, with operating cash flow of -$23.9M and free cash flow of -$24.4M in FY2025. Capital expenditures in FY2025 were $522,000, and the share count grew 32.6% over five years.

At $9.07 per share, ClearPoint Neuro has a market cap of $276.7M and an enterprise value of $491.8M. The stock trades at a price-to-sales multiple of 6.5x, above the 4.1x median of its US-listed Healthcare peers. Its forward P/E is 12.1x compared to the peer median of 17.3x, and its EV-to-revenue multiple is 11.6x. Over the past year, CLPT dropped 64.1%, while the S&P 500 (SPY) returned 16.8%. Over five years, the stock is down 49.5% compared to an 83.0% gain for the index.

Wall Street coverage includes 2 Strong Buy ratings, 0 Buys, 0 Holds, and 0 Sells. The mean price target is $23.50, representing an upside of 159.1% over the last close of $9.07. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $49.0M and EPS of -$1.30. For the following fiscal year, 2 analysts model revenue of $56.5M and EPS of -$1.20. ClearPoint Neuro recorded 0 EPS beats over the last 4 quarters, with its next earnings release scheduled for October 28, 2026.

This page is an AI-written research summary of ClearPoint Neuro, Inc. (CLPT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CLPT income statement, CLPT balance sheet, CLPT key metrics, CLPT analyst forecast, CLPT chart. See the CLPT stock overview for the latest quote and news.